Advanced Search

 

Study ID Status Title Patient Level Data
TRX106573 Completed A Study of Combination Product (sumatriptan succinate and naproxen sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Study Listed on ClinicalStudyDataRequest.com
TRX109011 Completed A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during the Moderate-Severe Migraine Pain, 1 of 2 Study Listed on ClinicalStudyDataRequest.com
TRX109013 Completed A Crossover, Randomized, Double-blind, Double-dummy, Placebo-controlled Study to Evaluate the Efficacy of TREXIMET®/Sumatriptan + Naproxen Sodium vs. Butalbital-containing Combination Medications for the Acute Treatment of Migraine when administered during Moderate-Severe Migraine Pain, 2 of 2 Study Listed on ClinicalStudyDataRequest.com
TXA107563 Completed A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) for a single moderate or severe headache in adults diagnosed with probable migraine without aura (ICHD-II 1.6.1) (*TREXIMET) Study Listed on ClinicalStudyDataRequest.com
TXA107977 Completed Study TXA107977, a Long-Term Safety Study of a Combination Product Containing Sumatriptan Succinate and Naproxen Sodium for the Treatment of Migraine in Adolescents Study Listed on ClinicalStudyDataRequest.com
U87TH-04 Completed Clinical Effect of Valaciclovir Hydrochloride (256U87) Tablets in Patients With Genital Herpes
UCP-95-053 Completed An Evaluation of Relative Bioavailability of Ondansetron From an 8mg Zydis® Formulation and an 8mg Zofran® Tablet
UCR/94/025FLN-261 Completed A double-blind, placebo-controlled trial to assess the safety of long-term treatment with fluticasone proprionate aqueous nasal spray
UK03 Completed Seven day administration of BW 430C (LAMICTAL) to normal volunteers- multiple dose pharmacokinetics and safety.
UK11 Completed Open one-week trial of lamotrigine as add-on therapy in patients with epilepsy.
UK113 Completed A comparison of the bioavailability of 100mg and 200mg lamotrigine (LAMICTAL) tablets in healthy volunteers.
UK120 Completed Comparative bioavailability of 5mg and 25mg blackcurrant flavoured, dispersible lamotrigine tablets with 25mg lamotrigine capsules.
UK25 Completed Lamotrigine: a single-blind dose-ranging study in patients with epilepsy.
US-01 Completed Acute Dose Safety and Pharmacokinetics Study of Lamotrigine and Placebo in Epileptic Patients
US01B Completed Wellbutrin: Preliminary pharmacokinetics
US14 Completed Chronic dose tolerance of lamotrigine (LAMICTAL®) and placebo in epileptic patients: A further evaluation.
US22 Completed An evaluation of the dose proportionality and bioequivalence of LAMICTAL® tablets in normal volunteers.
US47 (105-047) Completed A pilot bioequivalence study of US and UK manufactured 100 mg LAMICTAL® (lamotrigine) dispersible/chewable tablets in normal healthy volunteers.
US50 Completed Repeated bioequivalence study of US 25 mg Lamictal® compressed tablets, US 5 mg Lamictal® dispersible/chewable tablets and UK 5 mg Lamictal® dispersible/chewable tablets in healthy adult male volunteers.
USA30206 Completed A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and propofol regimen versus a fentanyl and propofol regimen, including an investigation of the pharmacokinetics of remifentanil and remifentanil acid, in Intensive Care Unit patient ...
USA30207 Completed A randomised, double-blind, parallel group, multi-centre study comparing the safety and efficacy of a remifentanil and midazolam regimen versus a morphine and midazolam regimen in Intensive Care Unit patients requiring analgesia and sedation in association with short-term mechanical ventilation.
USA30212 Completed An open label, non-comparator, multi-centre study to assess the safety, efficacy and pharmacokinetics of remifentanil in Intensive Care Unit patients with varying degrees of renal dysfunction requiring analgesia and sedation in association with mechanical ventilation.
USA30217 Completed A Randomised, open, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil HCL) + propofol/midazolam regimen versus fentanyl + propofol/midazolam or morphine + propofol/midazolam regimens in mechanically ventilated intensive care unit subjects with brain i ...
USA30225 Completed An economic evaluation of an analgesia-based sedation regimen with remifentanil supplemented with propofol compared to a conventional sedation regimen with midazolam/fentanyl in the ICU for patients after cardiac surgery
USA30226 Completed A randomised, open-label, multicentre, parallel group study comparing the safety and efficacy of an Ultiva (remifentanil hydrochloride) based analgesia/sedation regimen with a conventional sedative-based regimen in long-term ICU subjects requiring analgesia and sedation for up to 10 days. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.